For the month ended 31 May 2026, Touyun Biotech Group Limited reported no changes to either its authorised or issued share capital.

Authorised capital remained at 12.50 billion ordinary shares with a par value of HKD 0.04, equivalent to HKD 500.00 million.

Issued share capital closed the month unchanged at 2.81 billion ordinary shares. The company held no treasury shares over the period, and no new shares were issued or cancelled.

Touyun Biotech confirmed compliance with Hong Kong’s 25 percent minimum public-float requirement.

Share-option activity was limited to the lapse of 0.30 million options under a 2012 scheme (exercise price HKD 1.34). Outstanding options across all active schemes total 138.50 million, broken down as follows: • 0.60 million options at HKD 1.34; • 60.20 million options at HKD 0.60; • 77.70 million options at HKD 0.20.

No share options were exercised, no warrants or convertibles were outstanding, and the company raised no funds during the month.